A clinical trial for a weight loss drug includes only men aged 30-50 from one hospital. The results show the drug is effective. A doctor at another hospital wants to prescribe it to a 65-year-old woman. Why should the doctor be cautious?
- AThe trial's narrow inclusion criteria (men aged 30-50) limit generalizability; the drug's effectiveness and safety may differ for women and older patientsCorrect
- BThe drug was only tested at one dosage level
- CThe clinical trial was not double-blind
- DClinical trials always produce unreliable results
Why A is right
The trial studied a specific subpopulation (men aged 30-50 from one hospital). The drug's effects may differ by sex, age, and other factors not represented in the trial. Prescribing to a 65-year-old woman extends beyond the trial's scope of inference, so caution is warranted.
Why the other 3 choices miss
- B
- Incorrect because the number of dosage levels is not mentioned and is not the primary concern; the issue is the limited study population.
- C
- Incorrect because the blinding status of the trial is not mentioned and is not the primary reason for caution in this context.
- D
- Incorrect because clinical trials are the gold standard for evaluating medical treatments; the concern here is generalizability, not reliability.